Manning & Napier Advisors LLC Has $3.16 Million Holdings in Haleon plc (NYSE:HLN)

Manning & Napier Advisors LLC decreased its holdings in Haleon plc (NYSE:HLN) by 3.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 331,053 shares of the company’s stock after selling 11,557 shares during the period. Manning & Napier Advisors LLC’s holdings in Haleon were worth $3,158,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Procyon Advisors LLC grew its position in Haleon by 41.3% during the fourth quarter. Procyon Advisors LLC now owns 230,240 shares of the company’s stock valued at $2,196,000 after purchasing an additional 67,329 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Haleon by 27.2% during the 3rd quarter. HighTower Advisors LLC now owns 350,795 shares of the company’s stock valued at $3,701,000 after buying an additional 74,970 shares during the period. Jane Street Group LLC grew its holdings in shares of Haleon by 1,689.4% during the 3rd quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock valued at $2,803,000 after acquiring an additional 250,169 shares in the last quarter. Chartwell Investment Partners LLC increased its stake in shares of Haleon by 107.8% in the third quarter. Chartwell Investment Partners LLC now owns 475,415 shares of the company’s stock worth $5,030,000 after acquiring an additional 246,594 shares during the last quarter. Finally, Townsquare Capital LLC raised its holdings in shares of Haleon by 29.8% during the third quarter. Townsquare Capital LLC now owns 475,618 shares of the company’s stock worth $5,032,000 after acquiring an additional 109,217 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on HLN. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $10.95.

Haleon Stock Down 0.2 %

Shares of Haleon stock opened at $9.53 on Thursday. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The stock has a market capitalization of $43.12 billion, a P/E ratio of 28.01, a PEG ratio of 2.60 and a beta of 0.29. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock has a 50 day moving average price of $9.54 and a two-hundred day moving average price of $9.75.

Haleon (NYSE:HLN) last posted its earnings results on Thursday, October 31st. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.74 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. During the same period last year, the business posted $0.10 EPS. Equities analysts expect that Haleon plc will post 0.44 earnings per share for the current year.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.